<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03463525</url>
  </required_header>
  <id_info>
    <org_study_id>D5160C00043</org_study_id>
    <nct_id>NCT03463525</nct_id>
  </id_info>
  <brief_title>Open-label PET Study to Determine Brain Exposure With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases</brief_title>
  <acronym>ODIN-BM</acronym>
  <official_title>An Open-label PET Study to Determine Brain Exposure of Osimertinib After IV Microdose Administration of [11C]Osimertinib and Therapeutic Oral Doses of Osimertinib to Patients With EGFR Mutated NSCLC With Brain Metastases</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, single centre, Phase I study to determine the brain exposure of
      [11C]osimertinib in patients with EGFRm NSCLC with brain metastases.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single-centre, Open-label, PET imaging and Pharmacokinetic Study of IV Administered
      [11C]osimertinib in EGFRm Non-small cell lung cancer patients with brain metastases. The
      study will consist of 2 phases, an imaging phase and a continuous access phase.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 19, 2018</start_date>
  <completion_date type="Anticipated">November 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">November 25, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Brain Exposure to [11C]osimertinib in Tumour Region of Interest</measure>
    <time_frame>PET Scan on Day 1</time_frame>
    <description>Measurement of the brain standard uptake value (SUV) seen on PET scan at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib</measure>
    <time_frame>Blood samples collected on Day 1 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib by assessment of maximum plasma concentration (Cmax), derived from the curve taken at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Brain to Plasma Ratio of Area Under the Concentration Curve (AUC)</measure>
    <time_frame>Measurement collected on Day 1 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Measurement of the brain to plasma partition coefficient (concentration brain/plasma ratio) by assessment of area under the concentration-time curve, derived from the curve taken at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Radioactivity by Assessment of Time to Cmax (Tmax)</measure>
    <time_frame>Blood samples collected on Day 1 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib radioactivity by assessment of time to Cmax (Tmax), derived from the curve taken at baseline.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Exposure to [11C]osimertinib in Tumour Region of Interest</measure>
    <time_frame>PET Scan on Day 2</time_frame>
    <description>Measurement of the brain standard uptake value (SUV) seen on PET scan after a single dose of oral osimertinib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Brain Exposure to [11C]osimertinib in Tumour Region of Interest</measure>
    <time_frame>PET Scan on Day 29</time_frame>
    <description>Measurement of the brain standard uptake value (SUV) seen on PET scan after at least 21days of continuous oral osimertinib dosing.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib</measure>
    <time_frame>Blood samples collected on Day 292, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib by assessment of maximum plasma concentration (Cmax), derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib</measure>
    <time_frame>Blood samples collected on Day 2 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib by assessment of maximum plasma concentration (Cmax), derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Radioactivity by Assessment of Time to Cmax (Tmax)</measure>
    <time_frame>Blood samples collected on Day 2 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib radioactivity by assessment of time to Cmax (Tmax), derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Radioactivity by Assessment of Time to Cmax (Tmax)</measure>
    <time_frame>Blood samples collected on Day 29 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Pharmacokinetics of [11C]osimertinib radioactivity by assessment of time to Cmax (Tmax), derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Brain to Plasma Ratio of Area Under the Concentration Curve (AUC)</measure>
    <time_frame>Measurement collected on Day 2 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Measurement of the brain to plasma partition coefficient (concentration brain/plasma ratio) by assessment of area under the concentration-time curve, derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of [11C]osimertinib Brain to Plasma Ratio of Area Under the Concentration Curve (AUC)</measure>
    <time_frame>Measurement collected on Day 29 at 2, 4, 6, 8, 10, 15, 20, 30, 40, 50, 60, 75, and 90 minutes post-[11C]osimertinib injection.</time_frame>
    <description>Measurement of the brain to plasma partition coefficient (concentration brain/plasma ratio) by assessment of area under the concentration-time curve, derived from the curve taken during the treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib and its Metabolite by Assessment of AUC Metabolite to Parent Ratio</measure>
    <time_frame>Blood samples collected on Day 2 at pre-administration, 1, 2,4 and 6 hours post dose.</time_frame>
    <description>Pharmacokinetics of osimertinib and its metabolite by assessment of AUC metabolite to parent ratio, derived from the curves taken during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib by Assessment of Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Blood samples collected on Day 2 at pre-administration, 1, 2,4 and 6 hours post dose.</time_frame>
    <description>Pharmacokinetics of osimertinib by assessment of maximum plasma concentration (Cmax), derived from the curve taken during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib by Assessment of Area Under the Concentration-time Curve</measure>
    <time_frame>Blood samples collected on Day 2 at pre-administration, 1, 2,4 and 6 hours post dose.</time_frame>
    <description>Pharmacokinetics of osimertinib by assessment of area under the concentration-time curve from time zero to the last measurable time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib by Assessment of Time to Cmax (Tmax)</measure>
    <time_frame>Blood samples collected on Day 2 at pre-administration, 1, 2,4 and 6 hours post dose.</time_frame>
    <description>Pharmacokinetics of osimertinib by assessment of time to Cmax (Tmax), derived from the curve taken during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib and its Metabolite by Assessment of AUC Metabolite to Parent Ratio</measure>
    <time_frame>Blood samples collected on Day 29 at pre-administration, 1,2,4 and 6 hours post dose.</time_frame>
    <description>Pharmacokinetics of osimertinib and its metabolite by assessment of AUC metabolite to parent ratio, derived from the curves taken during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib by Assessment of Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>Blood samples collected on Day 29 at pre-administration, 1,2,4 and 6 hours post dose.</time_frame>
    <description>Pharmacokinetics of osimertinib by assessment of maximum plasma concentration (Cmax), derived from the curve taken during the treatment period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib by Assessment of Area Under the Concentration-time Curve</measure>
    <time_frame>Blood samples collected on Day 29 at pre-administration, 1,2,4 and 6 hours post dose.</time_frame>
    <description>Pharmacokinetics of osimertinib by assessment of area under the concentration-time curve from time zero to the last measurable time point.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Osimertinib by Assessment of Time to Cmax (Tmax)</measure>
    <time_frame>Blood samples collected on Day 29 at pre-administration, 1,2,4 and 6 hours post dose.</time_frame>
    <description>Pharmacokinetics of osimertinib by assessment of time to Cmax (Tmax), derived from the curve taken during the treatment period.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] with IV [11C]osimertinib administration</measure>
    <time_frame>From study Day 1 and until 30 days after the study drug is discontinued.</time_frame>
    <description>Collection and assessment of adverse events graded using CTCAE (version 4.03).</description>
  </other_outcome>
  <other_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events [Safety and Tolerability] with continuous oral osimertinib</measure>
    <time_frame>From study Day 1 and until 30 days after the study drug is discontinued.</time_frame>
    <description>Collection and assessment of adverse events using CTCAE (version 4.03)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">8</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>[11C]osimertinib + oral osimertinib</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IV microdose administrations of [11C]osimertinib co-administered with 80 mg daily oral osimertinib.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Osimertinib 80 mg once daily p.o. will be taken continuously by the patient from the day of the second PET exam.</description>
    <arm_group_label>[11C]osimertinib + oral osimertinib</arm_group_label>
    <other_name>Tagrisso</other_name>
    <other_name>AZD9291</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[11C]osimertinib</intervention_name>
    <description>Patients will receive 3 single IV microdose administrations of [11C]osimertinib and PET exams on: Day 1, Day 2 (or up to Day 8) and Day 29.</description>
    <arm_group_label>[11C]osimertinib + oral osimertinib</arm_group_label>
    <other_name>[11C]AZD9291</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female aged at least 18 years.

          2. Histological or cytological confirmation of diagnosis of NSCLC.

          3. For TKI-naïve patients, confirmation of EGFR mutation known to be associated with
             EGFR-TKI sensitivity (including G719X, exon 19 deletion, L858R, L861Q) as assessed by
             local and/or central laboratory via tissue/cytology is required.

          4. In patients who have had prior, EGFR-TKI such as gefitinib, erlotinib or afatinib,
             radiological documentation of disease progression while on a previous continuous
             treatment with an EGFR-TKI is required. In addition, other lines of therapy may have
             been given. Patients must have documented radiological progression on the last
             treatment administered prior to enrolling in the study and should harbour the T790M
             EGFR resistance mutation - determined in tissue/cytology or in plasma.

          5. Mandatory provision of FFPE tissue and/or blood sample for central confirmation of
             EGFR mutation status.

          6. Confirmed brain metastasis via MRI assessment.

          7. World Health Organisation (WHO) performance status 0 to 2 with no deterioration over
             the previous 2 weeks and a minimum life expectancy of 12 weeks.

          8. Females should be using highly effective contraceptive measures, and must have a
             negative pregnancy test prior to start of dosing if they are of child-bearing
             potential.

             Evidence of non-child-bearing potential fulfilled by by one of the following criteria
             at screening:

               -  Post-menopausal defined as aged more than 50 years and amenorrhoeic for at least
                  12 months following cessation of all exogenous hormonal treatments;

               -  Women under 50 years old would be consider postmenopausal if they have been
                  amenorrhoeic for 12 months or more following cessation of exogenous hormonal
                  treatments and with luteinising hormone (LH) and follicle-stimulating hormone
                  (FSH) levels in the post-menopausal range for the institution.

               -  Documentation of irreversible surgical sterilisation by hysterectomy, bilateral
                  oophorectomy or bilateral salpingectomy but not tubal ligation.

          9. Male subjects should be willing to use barrier contraception.

         10. Have a body mass index (BMI) between 18.0 kg/m2 and 30.0 kg/m2 inclusive and weigh at
             least 40.0 kg and no more than 100.0 kg, inclusive.

         11. Able and willing to participate in all scheduled evaluations, abide by all study
             restrictions, and complete all required tests and procedures.

        Exclusion Criteria:

          1. Participation in another clinical study with an investigational product during the
             previous 14 days (or a longer period, depending on the defined characteristics of the
             agents used).

          2. Treatment with any of the following:

               -  an EGFR-TKI (e.g, erlotinib, gefitinib or afatinib) within 10 days or at least 5x
                  the half-life, whichever is the longer, of the first administration of
                  investigational product.

               -  Any cytotoxic chemotherapy, investigational agents or other anticancer drugs from
                  a previous treatment regimen or clinical study within 14 days of the first
                  administration of the investigational product.

               -  Osimertinib in the present study (ie, administration with osimertinib previously
                  initiated in this study) or other studies. Patients who were enrolled, screened
                  but not dosed (ie, withdrew from the study prior to dosing) may be re-enrolled
                  and rescreened if in the opinion of the Investigator, the reason(s) for earlier
                  withdrawal no longer applies.

               -  Major surgery (excluding placement of vascular access) within 4 weeks of the
                  first administration of the investigational product.

               -  Radiotherapy (including brain) with a limited field of radiation within 1 week of
                  the first administration of the investigational product, with the exception of
                  patients receiving radiation to more than 30% of the bone marrow or with a wide
                  field of radiation which must be completed within 4 weeks of the first
                  administration of the investigational product.

               -  Patients currently receiving (or unable to stop use at least 3 weeks before
                  receiving the first administration of osimertinib) medications or herbal
                  supplements known to be potent inducers of CYP3A4.

          3. Any unresolved toxicities from prior therapy greater than CTCAE grade 1 with the
             exception of alopecia and grade 2, prior platinum therapy-related neuropathy.

          4. History of brain surgery or major brain trauma in the last year.

          5. Any evidence of severe or uncontrolled systemic diseases, including uncontrolled
             hypertension and active bleeding diatheses, or active infection including hepatitis B,
             hepatitis C and human immunodeficiency virus (HIV). Screening for chronic conditions
             is not required (hepatic impairment is excluded from this criterion).

               -  Any of the following cardiac criteria:

                    -  Mean resting corrected QT interval (QTc) &amp;gt;470 msec obtained from 3 ECGs,
                       using the screening clinic ECG machine derived QTc value.

                    -  Any clinically important abnormalities in rhythm, conduction or morphology
                       of resting ECG (eg, complete left bundle branch block, third degree heart
                       block,second degree heart block).

                    -  Any factors that increase the risk of QTc prolongation or risk of arrhythmic
                       events such as heart failure, hypokalaemia, congenital long QT syndrome,
                       family history of long QT syndrome or unexplained sudden death under 40
                       years of age or any concomitant medication known to prolong the QT interval.

          6. Past medical history of ILD, drug-induced ILD, radiation pneumonitis which required
             steroid treatment, or any evidence of clinically active ILD.

          7. Inadequate bone marrow reserve or organ function as demonstrated by any of the
             following laboratory values:

               -  Absolute neutrophil count &amp;lt;1.5 × 109/L;

               -  Platelet count &amp;lt;100 × 109/L;

               -  Haemoglobin &amp;lt;90 g/L;

               -  Alanine aminotransferase (ALT) &amp;gt;2.5 times the upper limit of normal (ULN) if
                  no demonstrable liver metastases or &amp;gt;5 times ULN in the presence of liver
                  metastases.

               -  Aspartate aminotransferase (AST) &amp;gt;2.5 times ULN if no demonstrable liver
                  metastases or &amp;gt;5 times ULN in the presence of liver metastases.

               -  Total bilirubin &amp;gt;1.5 times ULN if no liver metastases or &amp;gt;3 times ULN in
                  the presence of liver metastases or Gilbert's Syndrome.

               -  Creatinine &amp;gt;1.5 times institutional ULN concurrent with creatinine clearance
                  &amp;lt;50 mL/min (measured or calculated by Cockcroft-Gault formula).

          8. Refractory nausea and vomiting, chronic gastrointestinal diseases, inability to
             swallow the formulated product or previous significant bowel resection that would
             preclude adequate absorption of osimertinib.

          9. History of hypersensitivity to active or inactive excipients of osimertinib or drugs
             with a similar chemical structure or class to osimertinib.

         10. Judgment by the Investigator that the patient should not participate in the study if
             the patient is unlikely to comply with study procedures, restrictions and
             requirements.

         11. In addition, the following is considered criteria for exclusion from the exploratory
             genetic research:

               -  Previous allogenic bone marrow transplant;

               -  Non-leukocyte depleted whole blood transfusion within 120 days of the date of the
                  genetic sample collection.

         12. Patients on anticoagulant treatment.

         13. Absence of collateral flow between ulnar and radial artery as assessed by the Allen´s
             test.

         14. Suffering from claustrophobia and/or having implanted metal devices or implants such
             as pacemaker, vascular or heart valves, stents, clips, also metal deposits such as
             bullets, shells, metal grains in the eyes.

        16. Previous participation in a research PET or PET/CT study. 17. The following are
        exclusion criteria for contrast enhanced MRIs:

          -  Glomerular filtration rate &amp;lt;30 ml/min;

          -  History of renal insufficiency;

          -  Pregnancy. 18. Women who are breast-feeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Simon Ekman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Karolinska University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Karolinska University Hospital</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Simon Ekman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 20, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 13, 2018</study_first_posted>
  <last_update_submitted>March 12, 2018</last_update_submitted>
  <last_update_submitted_qc>March 12, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Carcinoma, Non-Small-Cell Lung</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

